Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $12.29 million. The enterprise value is $7.66 million.
Important Dates
The last earnings date was Wednesday, April 15, 2026, after market close.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 10.16 million shares outstanding. The number of shares has increased by 429.93% in one year.
| Current Share Class | 10.16M |
| Shares Outstanding | 10.16M |
| Shares Change (YoY) | +429.93% |
| Shares Change (QoQ) | +6.11% |
| Owned by Insiders (%) | 8.49% |
| Owned by Institutions (%) | 6.80% |
| Float | 5.96M |
Valuation Ratios
The trailing PE ratio is 1.45.
| PE Ratio | 1.45 |
| Forward PE | n/a |
| PS Ratio | 4.11 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 1.12 |
| EV / Sales | 2.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72
| Current Ratio | 0.72 |
| Quick Ratio | 0.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -62.80% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 3,379.02% |
| Weighted Average Cost of Capital (WACC) | 13.14% |
| Revenue Per Employee | $398,571 |
| Profits Per Employee | $980,714 |
| Employee Count | 7 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.94% in the last 52 weeks. The beta is 1.62, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -21.94% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 37.12 |
| Average Volume (20 Days) | 238,509 |
Short Selling Information
The latest short interest is 405,599, so 3.99% of the outstanding shares have been sold short.
| Short Interest | 405,599 |
| Short Previous Month | 411,637 |
| Short % of Shares Out | 3.99% |
| Short % of Float | 6.80% |
| Short Ratio (days to cover) | 3.32 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $2.79 million and earned $6.87 million in profits. Earnings per share was $0.83.
| Revenue | 2.79M |
| Gross Profit | 2.79M |
| Operating Income | -17.88M |
| Pretax Income | 9.17M |
| Net Income | 6.87M |
| EBITDA | -17.81M |
| EBIT | -17.88M |
| Earnings Per Share (EPS) | $0.83 |
Full Income StatementBalance Sheet
The company has $3.82 million in cash and n/a in debt, giving a net cash position of $3.82 million or $0.38 per share.
| Cash & Cash Equivalents | 3.82M |
| Total Debt | n/a |
| Net Cash | 3.82M |
| Net Cash Per Share | $0.38 |
| Equity (Book Value) | -629,000 |
| Book Value Per Share | -0.07 |
| Working Capital | -3.17M |
Full Balance SheetCash Flow
| Operating Cash Flow | -18.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 61,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -18.19M |
| FCF Per Share | -$1.79 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -640.68% and 328.67%.
| Gross Margin | 100.00% |
| Operating Margin | -640.68% |
| Pretax Margin | 328.67% |
| Profit Margin | 328.67% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Traws Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -429.93% |
| Shareholder Yield | -429.93% |
| Earnings Yield | 59.81% |
| FCF Yield | -158.44% |
Analyst Forecast
The average price target for Traws Pharma is $8.00, which is 561.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 561.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 84.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on September 23, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Traws Pharma has an Altman Z-Score of -89.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -89.3 |
| Piotroski F-Score | 2 |